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DISCLAIMER:  While the workshop was co-sponsored by the NCI and RSS, the 
comments in this report are strictly the opinions of the co-authors and does not 
constitute endorsement of these results and/or treatments by the NCI and RSS or 
consensus of all the co-authors on each of the points. This report is designed to 
stimulate further formal research and development to explore the future clinical 
application of these novel therapies and not for implementation into routine clinical 
practice.  
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The National Cancer Institute’s Radiation Research Program in collaboration with the 
Radiosurgery Society hosted a workshop on Understanding High-Dose, Ultra-High 
Dose rate and Spatially Fractionated Radiotherapy on August 20-21, 2018 to bring 
together experts in experimental and clinical experience in these and related fields.  
Critically, the overall aims were to understand the biological underpinning of these 
emerging techniques and the technical/physical parameters that must be further defined 







































Historical and current perspectives of Spatially Fractionated Radiation Therapy  
(SFRT) 
Several SFRT or ultra-high dose rate experimental and clinical regimens are being 
studied pre-clinically with some early clinical experience available: GRID, FLASH, 
LATTICE Radiotherapy (LRT), and Microbeam Radiation Therapy (MRT). The common 
aims of SFRT or FLASH methods are to achieve better tumor control and/or reduced 
damage to normal tissue. Mechanisms might be shared, but currently not well 
understood. Bystander, abscopal effects, vascular damage, angiogenic and immuno-
responses have all been proposed to be involved (Fig.1).  
 
 
Biology of SFRT 
Research and clinical results from traditional GRID-type SFRT studies were the initial 
focus of the meeting.    Patients with very large bulky tumors (≥ 6 cm) present a real 
therapeutic challenge to the treating physicians. These large tumors may be found at 
initial presentation or are also commonly present as recurrences in patients who have 
already received maximum surgery, chemotherapy or radiotherapy.  Novel therapeutic 
approaches are needed in order to offer additional treatment options to these patients.  
The concept of GRID has been around for many years, developed as a means of 
reducing skin injury with the low energy X-rays available then. The idea was to place an 
absorbing grid directly on the skin of the patient, in order to reduce the dose to the basal 
cells of the skin directly under the grid. This grid would be out of focus a few millimeters 
further into the tissue and would therefore not affect the dose distribution in a deeper 
lying tumor (1).  Yet it has not been studied in great detail as now used with high 
energy, deeply penetrating beams.  Therefore, the possible biological mechanisms and 
extent to which GRID contributes to overall tumor control in the context of modern-day 
chemoradiation regimens are not clearly understood.  While a number of provocative 
case studies were presented, there were limited or no comparative data presented 
between radiation therapy with and without SFRT, an aspect felt to be an important step 
in determining appropriate clinical application. 
 
The opening session of the meeting was on biology, which aimed to demonstrate the 
biological underpinnings of various approaches utilizing spatial fractionation from 
laboratory experiments. Technology driven evolutions in radiation oncology were 
highlighted, which have enabled advanced conformal delivery techniques with dose 
delivery characteristics that share common features with SFRT on the scale of micron 
and centimeter wide beam diameters. In vitro and in vivo evidence supporting radiation 
induced signaling including bystander and abscopal effects, as potential mediators of 
response to SFRT were presented.  The role of bystander effects was discussed as a 
potential explanation for SFRT responses followed by theoretical simulations of 
radiation-induced signaling for laboratory-based GRID beam geometries. Further 
evidence was presented demonstrating the biological effects of spatial fractionation on 
normal tissue vasculature and immune response along with clinical examples of 
radiation-induced signaling that included abscopal effects. In summary, current 
evidence using SFRT parameters scaled to fit experiments in the laboratory and not the 
exact patterns used in clinical practice geometry implicates multiple radiobiological 
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response mechanisms that need to be further studied, quantified and optimized to 
evaluate the efficacy and, as possible, develop the full potential of spatial fractionation 
for improving therapeutic index. 
 
A number of data sets were also presented to describe spatial fractionation and the 
biological response of solid tumors to this type of radiotherapy.   Preclinical studies 
employing a small animal conformal irradiation system have suggested that some of the 
biological mechanisms of action are related to bystander killing as well as vascular 
damage and re-modeling leading to improved tumor oxygenation (2-4).   These aspects 
of biological response by the tumor have been studied in both aerobic and hypoxic 
conditions, and it was found that hypoxia modifies the bystander killing in some cases.  
In addition, it was observed that an inhibitor of angiogenesis could increase the effect of 
GRID and that the addition of thermal ablation to single dose GRID greatly improves 
tumor control in an orthotopic rat breast tumor model when added to a multi-modality 
therapy regimen (5) . Critical to these studies is the physical definition of the treatment 
technique, including the size of the higher and lower dose volumes with the SFRT field. 
 
A special emphasis was given to Microbeam Radiation Therapy (MRT) as an 
experimental regimen as well.  This approach of SFRT, which demonstrated better 
tumor control and normal tissue tolerance in animal models at very high doses, 
especially for brain tumors, had demonstrated that (bystander) induced differentiation 
played a role and could be used for benign conditions.  In general, the orthovoltage 
mini-beam may have value due to the very high peak to valley dose ratios that can be 
obtained in comparison to high energy/high dose SFRT type of therapy. 
 
In many cases advanced tumors are clinically radio- and chemo-resistant due to poor 
blood flow, hypoxia and low pH in the tumor. These factors may also influence the 
degree of bystander effects or immune surveillance generated by GRID therapy of the 
tumor. Clearly, large tumor volume has been found to correlate with decreased local 
control and survival in patients receiving conventionally fractionated chemoradiation for 
cancers such as head and neck, lung and breast. Thus, treatment modalities such as 
GRID radiation that can increase the tumor total dose and possibly activate beneficial 
bystander and abscopal immune effects while minimizing effects to normal tissues offer 
promising treatment options.  Other data has suggested that there are 
abscopal/systemically expressed effects when SFRT is focally applied to a locally 
advanced tumor, and that they may be equal to or greater than those observed in 
standard whole tumor radiotherapy at high dose/fraction (6).  Other groups have 
reported similar and fascinating trends in tumor immunity and control with partial 
radiation exposures (7,8).  Older reports have demonstrated that GRID radiotherapy 
may induce TNF-α, which might be an underlying mechanism for purported 
immunological effects (9).  These studies need to be greatly expanded into multiple 
models and confirmed in clinical trials.  The use of SFRT at present needs to be tested 
in patients receiving immunotherapy to evaluate the benefit of non-uniform fields on 
current cancer management practices.  Taken together, related work from a number of 
different centers in the last 10+ years suggest a potential of safely and effectively 
including GRID or a related approach termed Lattice radiotherapy (described below) 
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against a variety of tumor types in combination with standard of care regimens to 
maximize tumor control (10-14). 
 
Technical and clinical implementation of SFRT 
SFRT by definition, divides treatment volume into fractional sub-volumes with high and 
low doses alternating between the sub-volumes. Accordingly, GRID (the first type of 
SFRT introduced in early 1950s, (15), LATTICE and MRT are all considered as SFRT.  
While MRT is still at the stage of preclinical study, GRID and LATTICE have been 
implemented clinically. This section will focus on the technical and clinical aspects of 
GRID and LATTICE therapies. 
 
The early inception of GRID therapy was based on the objective of sparing normal 
tissue especially skin, while delivering an effective palliative dose to bulky tumors in the 
early days of orthovoltage therapy. GRID therapy being applied clinically with 
megavoltage beams uses a grid-pattern radiation fluence, which is created by the use of 
either a grid physical block (commercially available block) (16) software generated 
virtual block, or a multi-leaf collimator (MLC) modulation (17).   Following the convention 
of early GRID orthovoltage practice, the size of grid openings (peaks) and the 
separation (valleys) are typically near 1 cm. Proton beams have also been used to 
deliver GRID therapy, with similar spatial arrangements (18). Traditionally, GRID 
therapy refers to peak-valley distributions arranged in 2D. LATTICE is a 3D extension of 
traditional GRID treatment, in which, a number of high dose regions (sphere-like 
vertices that are planned to receive in the range of 15-20 Gy) are separated by low dose 
regions (19). The size of high dose vertices and distance between them closely 
resemble that of GRID, although not rigorously adhered to. No normal tissue outside of 
tumor volume will receive high dose as part of the treatment planning goals for 
LATTICE. LATTICE radiation therapy (LRT) can be delivered by photon-based IMRT, 
VMAT, robot-driven converging beams, or by charged particle beams. 
 
For the past decade, GRID therapy, although not a mainstream treatment modality, has 
been used by a number of clinicians to  treat many patients who they consider would 
have otherwise been denied other treatment options (20) and they are encouraged by 
their observations. Mohiuddin et al. (21) reported that among 71 patients and 87 sites 
treated, presenting with a variety of cancer types treated with GRID therapy with 15 Gy 
peak dose as a goal there was a 78% response rate for pain and no grade 3 toxicities 
were observed in any patient.  When GRID therapy was followed by conventionally 
fractionated external-beam therapy (open-field), a clinical complete response was seen 
in 5/8 patients and pCR was found in 50% of resected specimens.  The complete 
response in patients treated with an open-field external-beam radiation doses of 40 Gy 
or greater was higher than that seen in patients treated with lower doses.  Mohiuddin’s 
experience indicated that GRID therapy applied before open-field treatments appears to 
significantly and safely improve the response of tumors in a dose dependent manner, 




LRT, although relatively new, has already been applied to over a hundred patients in a 
number of clinical indications, including cervical squamous cell carcinoma, ovarian, and 
non-small cell lung cancer with excellent local control and minimal toxicity when 
delivering a single LRT up to 18 Gy to the vertices and around 3 Gy to the surrounding 
volume between each vertice (12,13). Currently, the dosimetric consideration of photon-
based LRT falls generally in the category of IMRT, VMAT, and stereotactic body 
radiotherapy (SBRT). In LRT, the dose is prescribed to the maximum dose of vertices. 
The cumulative empirical clinical experience presented at the workshop was a start to 
developing useful guidelines to begin a new LRT program which requires standardized 
definition and terminology to allow for multi-center trials with well-defined prescriptions, 
a goal of this workshop.  
 
The dosimetry of clinical GRID treatment is different from conventional RT and has 
been carefully studied and published (16,22). With the assistance of experienced 
physicists from a number of clinical centers having active GRID programs, implementing 
GRID therapy is readily feasible. The dose of GRID therapy has been traditionally 
prescribed to the depth of maximum dose along the beam path.  Furthermore, with 
advancements in the physical parameters of GRID and LATTICE (size of grid, peak-
valley dose ratio, etc.) additional studies are needed to validate and optimize these 
parameters at the biological level. Accordingly, technical improvements of 
GRID/LATTICE will rely heavily on progress in radiobiology and systematic clinical 
studies. Today, there are few clinical trials of GRID therapy (23) and given the empirical 
and encouraging clinical data, there is an urgent need for more systematic clinical 
studies.  In recognition of the lack of uniformity in historical clinical practice of 
GRID/LATTICE, a major emphasis has been placed on standardizing the physics and 
dosimetric aspects of the techniques, as well as in defining clinical endpoints.  But 
before we can proceed to clinical trials, there needs to be consensus on the dose, 
fractionation and physic quality assurance process for GRID/Lattice therapy based on 
current knowledge of this approach across the different institutions. Moreover, 
agreements on the clinical indications that would likely best benefit from this SFRT will 
help guide the design and focus of clinical trials. An active working group has been 
established to address these points. 
 
Clinical trials for ultra-high-dose rate or SFRT 
The clinical progress made in GRID, LATTICE and synchrotron-generated microbeams 
was reviewed, with an aim of discussing potential multi-center clinical trials that can and 
should be pursued in an attempt to reduce normal tissue toxicities and/or even improve 
tumor control. 
 
SFRT is an attractive treatment approach that enhances normal tissue-sparing and has 
encouraging observations in otherwise challenging palliative care situations.  Future 
clinical trials of SFRT should investigate its differential effect on the immune system.  
Specifically, single fraction delivery of high dose irradiation, as is performed for SFRT or 
other more mainstream approaches like SABR, may have immunological effects that 
differ substantially from conventional fractionation (24).  Alternatively, larger doses per 
fraction may impair immune response (25).  Furthermore, the peak-valley differential 
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dose effect could potentially optimize immunological processes that can result in 
abscopal effects (26).  Proton-based SFRT may have its own immune benefits while 
also allowing for absolute fall off of irradiation dose distal to the target volume.  In that 
induction of immune response can vary for the different target tissues (tumor, 
vasculature, immune infiltrate, stroma, etc). the timing of SFRT, use of one of multiple 
fractions, timing between SFRT and open field, etc, may have a critical impact on 
optimizing efficacy and of using this with immuno-modulators. 
 
Synchrotron-generated microplanar beams (microbeams) are another attractive 
modality to test, due to its minimal beam divergence allowing for extremely sharp dose 
deposition along the beam path, which can facilitate hundreds to thousands of Gy to be 
delivered to microscopic tissue slices while dramatically reducing the risk of 
radionecrosis (27).  This limited toxicity detected is attributed to the relative 
radioresistance of normal large vessels to high doses delivered in microbeams and the 
rapid regeneration of normal microvessels.  Moreover, spatial fractionation delivered 
with this modality allows for valleys of very low dose regions (28).  Microbeam treatment 
of solid tumors allows the delivery of doses up to 1000 Gy with selective damage to the 
tumor and general preservation of healthy tissues (29).  Microbeam radiosurgery has 
been investigated in vivo to ablate or transect selection central nervous system 
structures thought to contribute to such disorders like Parkinson’s Disease, Huntington’s 
Disease, and seizure disorders (30).  Aside from the tight dosimetry, the low energy of 
monochromatic beams makes them well-suited to treat superficial targets within the 
brain.  MRT is currently being pursued in the preclinical settings, where it is highly 
anticipated that clinical indications ranging from cancers to functional brain disorders will 
be evaluated for upcoming clinical trials. 
 
Brachytherapy and High Dose Rate versus GRID/Lattice/Flash: How can we 
exploit the understanding and impact of GRID/Lattice based on the success of 
brachytherapy in the clinic?    
Potential parallels and synergies between GRID/Lattice therapy and brachytherapy (BT) 
were explored.  The most obvious similarity between these two treatment approaches is 
the inherent heterogeneity in dose distribution, particularly with interstitial BT, where 
“peak” and “valley” doses commonly show a 4- to 6-fold difference.   
 
Clinical evidence supporting the use of monotherapy or combinatorial BT has shown 
high rates of tumor response and disease control, and this appears mirrored by the 
preliminary evidence supporting the use of GRID/Lattice therapy. Although it can be 
argued that these improvements are entirely a consequence of the dose-escalation 
achieved with BT, the panel felt that the dose inhomogeneity of BT may play a role.  For 
example, evidence in prostate cancer has suggested that conventional dosimetric 
parameters of overall BT dose are insufficient to explain the variability in outcomes (31).  
The study of this heterogeneity could uncover relevant biological mechanisms.  
Similarly, in cervical cancer the recent use of image-guided BT has been associated 
with higher local control rates and potentially improvements in survival compared to 
historical outcomes using intracavitary-only approaches (32,33).  These advancements 
in outcomes could be in part explained by a better definition of the target volume and 
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enhanced dose coverage.  However, considering the increased use of interstitial BT 
component in over 40% of image-guided BT treatments (32), the higher dose-
heterogeneity from the increasing interstitial component may also contribute to the 
observed improvements in outcomes.  
 
While many parallels exist between interstitial BT and GRID/Lattice therapy, the “peak-
to-valley” dose differential is generally greater and steeper in BT compared to 
GRID/Lattice dose distributions although further determination of the dose delivered 
versus dose-planned for GRID/Lattice will be informative. Moreover, the impact of 
motion on GRID/Lattice may smooth out dose heterogeneity while BT should hold their 
different peaks and valley dose differentials.  Similarly, the optimal valley dose (across 
the entirety of the tumor), the extent and spatial distribution of dose inhomogeneity, and 
additionally the temporal distribution of dose (time interval between treatments) are yet 
to be determined.   
 
High-precision anatomical and functional/molecular imaging is an important component 
of tumor response assessment and integral to mechanistic studies of understanding and 
optimizing SFRT.  Anatomical imaging precisely quantifies volumetric tumor response. 
The volumetric parameters can be augmented by imaging assessment of 
functional/biologic tumor characteristics, such as tumor microcirculation, hypoxia, 
cellularity and metabolic activity based on various molecular imaging tracers, and can 
correlate spatial dose distributions with the spatial metrics of functional tumor response 
(34).  These functional/molecular tissue properties are distributed heterogeneously 
throughout the tumor volume.  Therefore, in the context of heterogeneously delivered 
radiation doses, incorporation of functional/biologic and anatomic imaging provides a 
unique opportunity to longitudinally assess changes non-invasively, providing insight 
into tumor properties on a sequential whole-tumor scale.  
 
Tissue correlation of tumor biopsies at BT and dose correlation may allow BT to serve 
as a good test bed for molecular correlates in Lattice/GRID. While tumor tissue 
collection for translational research has been challenging in solid tumors, BT uniquely 
enables correlative translational studies to interrogate direct and indirect effects of 
radiation (e.g. molecular mechanisms of abscopal, bystander, vascular, and immune 
responses).  These correlates may help elucidate, in the context of clinical trials, an 
improved understanding of the role of immunomodulation and priming of 
immunotherapy (6).  Tumor biopsies can be seamlessly integrated into a BT procedure, 
and tissue samples correlated with high resolution anatomic and functional imaging 
(35), including spatial variations in dose. Moreover, tissue collection can be obtained 
repeatedly in fractionated high dose rate procedures for longitudinal assessment of 
molecular tissue correlative markers (36).  Co-location of these tissues correlates with 
the functional/molecular imaging parameter maps of cellularity (DWI MRI), vascularity 
(DCE MRI, DCE CT) and molecular tumor biomarker properties (PET tracers of 
glycolysis, proliferation and others) (34), which are now entering the BT paradigm (37) 
will be crucial. In turn, robust and validated non-invasive imaging biomarkers could be 
translated into clinical studies to refine treatment planning and response assessment.  
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Clinical trials leveraging BT for the exploration of GRID/Lattice therapy hypotheses 
should rely heavily on clinical outcome endpoints (or validated surrogates), such as 
quantitative tumor response, metastasis-free and overall survival rates, and strong 
translational components through tissue correlation pre-, post-, and potentially during 
therapy for longitudinal assessment. Incorporation of functional/molecular imaging-
based response assessment of vascular and metabolic effects can be considered to 
advance our understanding of molecular mechanisms in spatial/temporal 
heterogeneous dose delivery in patients. The potential for assessing tumor and immune 
response through circulating biomarkers will be critical for SFRT and for integration of 
radiation oncology in immuno-oncology progress.  
 
Biological effects of FLASH-RT and MRT 
Ionizing radiation provides an effective means for killing mammalian cells, and the field 
of radiation oncology specializes in using this physical agent to preferentially kill cancer 
cells while minimizing adverse outcomes to the surrounding normal tissue.  This session 
was devoted to rationalizing the potential benefits of two non-traditional irradiation 
modalities, namely MRT and FLASH-RT.  The use of MRT has received attention over 
the years due to the ability to modulate the spatial distribution of dose, based on the 
dramatic “peak and valley” dose differentials that can be obtained with GRID (29,38).  
The emergence of ultra-high dose rate irradiation known as FLASH-RT implements 
mean dose rates in excess >40 Gy/s, delivered as a single or a few pulses over 
intervals of milliseconds (39) .  While past reports have referred to mean dose rates, this 
in fact may be inadequate to properly describe the necessary FLASH parameters, as 
discussed further below.  In any case, these variations in beam delivery are in marked 
contrast to more traditional clinical irradiation modalities that implement more 
homogeneous irradiation fields typically delivered at much lower dose rates (~0.03 
Gy/s) and over the timeframe of minutes.  Session participants focused on the 
differential impact of MRT on the vasculature, and the preferential sparing of normal 
tissue complications without compromising tumor control by FLASH, features that are 
discussed further below. 
 
MRT 
The main limiting factor to further increase therapeutic radiation doses and the related 
tumor control for patients with cancers of unmet clinical need is the severe toxicity 
induced in vital healthy tissues by the treatment itself (40). Synchrotron X ray 
microbeams have been recognized since the 1980s as a unique therapeutic opportunity 
to overcome this dose limitation (41). This enticing possibility has elicited scientific 
interest across the world in radiotherapeutic applications of microbeams, referred to as 
MRT. MRT consists of a spatially modulated microscopic dose array of low energy X-
rays of 50 to 300 keV delivered at exceptionally high dose rates (up to 16 kGy/s). These 
spatially fractionated microscopic beams exploit the dose-volume effect leading to 
extraordinary normal tissue tolerance that triggers an entire cascade of differential 
biological effects able to improve tumor control.  
 
Decades of careful pre-clinical studies have consistently demonstrated the therapeutic 
efficacy of MRT in different tumor models such as gliosarcomas, squamous cell 
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carcinoma and breast carcinoma (29,42-44).  Normal tissues, which included the brains 
of adult rats, the caudal fin of zebrafish, immature tissues in suckling rats, duck 
embryos, the chick chorioallantoic membrane (CAM) and piglets have all showed a 
resistance of normal tissues to micro-beam irradiation applied in the MRT mode when 
compared with conventional uniform field irradiation (38,45-49).  Importantly, a long 
term study using the normal mouse ear pine (containing many types of tissues) 
demonstrated clearly that normal tissues such as skin, glands, cartilage, blood and 
lymphatic vessels are highly tolerant to MRT after entrance doses up to 800 Gy (50).  
 
Unpublished data in a study initiated by Varian Medical Systems (Palo Alto, CA, USA) 
indicated that MRT induces only minor patchy pulmonary fibrosis one-year post 
irradiation, following peak entrance doses of a few hundred Gy. MRT has the potential 
to control lung tumors with minor side effects, currently one of the major medical 
challenges in radiation oncology. While the pre-clinical evidence obtained in animal 
models strongly supports the potential clinical benefits of MRT questions do remain.  
The ultimate implementation of MRT as a new paradigm for cancer care will be 
facilitated by a deeper understanding of the underlying biological mechanisms 
responsible for the differential effects of MRT between tumors and normal tissue. 
Elucidating the relevant molecular pathways will help identify the most effective 
treatment protocols for future clinical trials. 
 
Recently performed studies using murine tumor models and in vivo CAM and zebra fish 
fin assays demonstrated that MRT is able to disrupt the immature (tumor) vessels by 
preserving the normal vasculature of the surrounding tissue (47). In addition, MRT 
triggered an acute inflammatory response (eventually also a late immune response) 
restricted to the immature tumor vessels or regenerating tissue (49). Those data 
indicated that MRT can be used as a novel angiodisruptive cancer treatment strategy. 
MRT represents a simple and unique method that can destroy immature tumor-vessels 
while sparing mature normal-tissue vessels from radiation damage.   When the dose 
delivered is in the range of 100-300 Gy, MRT causes a partial disintegration of the 
endothelium leading to a temporal but significant increase in tumor blood vessel 
permeability. We termed this phenomenon “MRT-induced vascular permeability 
window,” and it has been identified as potentially important for drug delivery. Finally, the 
MRT-irradiated blood vessels could serve as a homing beacon for circulating immune 
cells, thereby possessing the potential to modulate the anti-tumor immune response.  
 
FLASH-RT  
Ultra-high dose rate irradiation (in sub-second time scales), coined “FLASH-
radiotherapy” (FLASH-RT) by Favaudon et al. in 2014 (39), has gained attention 
because of the surprising observation in preclinical studies of model in vivo systems 
finding markedly increased therapeutic index compared to conventional dose rate 
irradiation that is delivered over minutes. Importantly, the ultra-short time of radiation 
delivery distinguishes the FLASH-RT modality from current radiotherapy.  It saturates 
the irradiated tissue bed within microseconds producing an instantaneous burst of free 
radicals whereas irradiation at conventional dose rates produce free radicals in a more 
chronic manner transpiring over minutes (51,52).  This initiates a series of reactions that 
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are qualitatively similar but quantitatively distinct so as to elicit markedly different 
biological responses to the initial deposition of damage that remains linear with the 
absorbed dose (53).  In fact, normal tissue sparing by FLASH has been described at 
least as far back as 1966 (54), attributed to the depletion of oxygen in tissues at very 
high dose rates (55), but in the last few decades this line of research has been relatively 
dormant until this recent renaissance of interest.   While the precise mechanisms 
underlying the differential response of tissues to FLASH-RT remain to be elucidated, 
careful dosimetry using 4 distinct calibrated systems have indicated clearly, that the 
measured differences in biological response observed between FLASH and lower dose 
rate delivery systems is simply not the consequence of different absorbed doses (56-
59).  Importantly, if not remarkably, the beneficial effects of FLASH-RT were first 
elucidated in vivo using preclinical mouse models (39,58), rather than using in vitro cell 
systems or more simplistic model organisms such as yeast, worms and flies.  
 
Normal tissue toxicities generally limit the maximum dose that can be delivered to the 
tumor bed without compromising patient safety (40,60,61).  These empirically derived 
relationships have evolved over years of clinical experience and define the dose limits 
that can be and have been modulated through changes in fractionation schedules and 
access to IGRT.  Clearly, any strategy capable of minimizing normal tissue toxicity has 
the potential for promoting dose escalation to the tumor bed, increasing the chances for 
local regional control and progression free survival.  Since the seminal paper by 
Vozenin and colleagues (39), FLASH-RT has been shown to dramatically spare normal 
tissue toxicities in multiple organ sites including, the lung, gut, skin and brain (58,62-64).  
Importantly, in late responding tissues, adverse functional outcomes such as lung 
fibrosis and neurocognitive decline typically found after conventional radiotherapeutic 
regimes can be minimized or even avoided when radiation doses are delivered at ultra-
high dose rates.   
 
The phenomenon of the increased therapeutic index of FLASH compared to 
conventional dose rate irradiation, or the “FLASH effect,” has now been reported in 
multiple preclinical models. Normal tissue sparing by FLASH of multiple organ systems 
including lung, brain, intestinal tract, and skin has been demonstrated in multiple mouse 
strains and even additional species (cat and mini-pig), while equal (and in some cases 
superior) tumor killing between FLASH and conventional dose rate has been observed 
across multiple in vivo tumor models (58,62,63).  The burgeoning field of FLASH-RT is 
now populated with more recent reviews than solid data driven manuscripts, and some 
confusion has emerged concerning the optimal beam parameters required to elicit the 
“FLASH effect”.  To remedy further and unnecessary uncertainty, it seems logical that 
authors claiming to evaluate FLASH-RT, should be required to provide the critical beam 
parameters used in a given study.  Without this information, as was the case in a recent 
report claiming a “negative” FLASH effect (65), it is virtually impossible to properly 
evaluate any conclusions drawn and place them in proper context within this expanding 
and evolving discipline.  Indeed, the group in Lausanne Switzerland led by Dr. Vozenin 
has suggested just such course of action, and has stressed that quoting mean dose 
rates may be an oversimplification of the important time signatures of a pulsed FLASH 
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beam.  In this light, a more accurate definition of the ultra-high dose rate parameters 
needed to trigger the FLASH effect is presently defined in terms of instantaneous intra-
pulse dose rates (≥ 104 Gy/sec) and overall time of exposure less than 100 milliseconds 
(i.e. ≤ 0.1 sec) (66). 
 
Given the nascent state of the field, a large portion of experimental observations to date 
remain preliminary and unpublished, and many questions remain unanswered 
particularly with respect to mechanism. While there are data suggesting a fundamental 
physical-chemical effect (i.e., radiochemical depletion of oxygen at FLASH dose rates), 
modulation of inflammatory cytokines (e.g., TGF-β) and differential immunologic 
responses between tumor and normal tissues have also been observed, which might be 
either downstream effects or independent mechanisms.  Provocative data presented at 
the workshop showed that FLASH irradiated mice bearing orthotopic brain tumors 
exhibited improved performance on a learning and memory task compared to mice 
subjected to conventional dose rate irradiation.  Importantly, the neurocognitive benefits 
afforded by FLASH-RT relative to standard dose-rate RT were substantiated further 
using a variety of learning and memory tasks and extended to reductions in anxiety, 
depression and improved fear extinction.  These findings demonstrated long-term and 
persistent (6 month) benefits that could be achieved with FLASH-RT, thereby avoiding 
the debilitating neurocognitive complications normally associated with conventional 
dose rate irradiation.  Additional data sets pointed to several potential underlying 
mechanisms able to explain the FLASH effect, and included reduced neuroinflammation 
and a preservation of host neuronal morphology. Certainly, we have barely scratched 
the surface of potential mechanistic pathways to be investigated. These normal tissue 
benefits portend a change in the field of radiation oncology, which necessitates a 
consideration of the effects of FLASH-RT on tumor control among other topics as 
discussed further below. 
 
FLASH – challenges, issues, strategies and hurdles for clinical trials 
The clinical relevance of FLASH has been limited by the lack of practical technologies to 
deliver such rapid treatments to human patients with typically deep-seated macroscopic 
tumors. However, this is poised to change with recent advances in linear accelerator 
technologies. Thus, the question of how to implement clinical trials for translation of 
FLASH is ripe for discussion.  In this light, an improved understanding of mechanisms 
from preclinical studies would inform more optimal designs of clinical trials.  While this is 
being studied using in vitro and in vivo models, clinical trials can now be considered.  
With electron-based delivery, the first clinical trials may be most ideal if performed in 
small to moderately size tumors in locations amenable to surgical salvage should 
incomplete tumor control be achieved with FLASH or there is a need for procedural 
intervention of a radiation-induced toxicity.  Superficial targets may also have additional 
translational endpoint benefits, including allowing for serial biopsies for histologic, 
genetic, and immunologic analyses, as would targets being treated preoperatively.  
Proton-based delivery may allow for additional sites to be considered for clinical trials.  
Very recently, the group at the University of Pennsylvania has described the 
development of a proton-based system for delivering FLASH-RT, which will prove useful 
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in defining further the limits and capabilities of this innovative radiation modality (67).  
To date, very little data on FLASH exist outside of single large fractions, and the utility of 
fractionated FLASH therapy or the combination of FLASH with chemotherapy or 
immunotherapy is not well characterized, and additional data with these approaches are 
needed before clinical trials.  Thereafter, if determined safe and feasible in humans, 
future randomized phase 2 trials could be considered comparing FLASH to conventional 
dose rate SABR and/or conventionally fractionated radiotherapy for selected indications, 
particularly for tumors where there is currently a high incidence of measurable toxicity 
with the best standard of care. 
 
It should be emphasized that the capability of FLASH-RT to spare normal tissue 
complications must be tempered under the possibility that such protective effects might 
also extend to the tumor, a clearly undesirable outcome.  This topic was addressed 
directly during the workshop where data derived from three independent tumor models 
showed that single fraction doses of either FLASH or conventional dose rate irradiation 
were equally efficient at delaying tumor growth (Montay-Gruel, unpublished data).  
Flank tumors, spontaneous tumors and orthotopic brain tumors of relevance to 
glioblastoma multiforme (GBM) were all equally responsive to either irradiation modality 
(Montay-Gruel, unpublished data).  Data shown demonstrated convincingly that FLASH-
RT did not spare the tumor, but rather, was isoefficient at tumor control when compared 
side-by-side with conventional dose rate irradiation.  While additional investigations 
using higher tumor control doses delivered as either single or multifraction regimes 
using FLASH-RT are clearly warranted, data to date does NOT indicate that tumor 
control is compromised by FLASH-RT. 
 
Moreover, the FLASH effect is incompletely characterized even from a 
phenomenological standpoint. Evidence to date suggests that a dose rate threshold of 
approximately 40 Gray/second or higher is needed to produce the FLASH effect, with 
potential improved normal tissue sparing at even higher dose rates (39,58). However, 
the accelerator-based radiation delivery systems used for FLASH experiments to date 
produce pulsed radiation, and there are many aspects to delivery speed – total dose 
and delivery time, dose per pulse, pulse timing structure, etc. – that may be critical to 
the effect and have not been comprehensively evaluated, since an exhaustive study is 
an experimentally daunting combinatorial problem. Clinical radiation therapy is 
predominantly fractionated, but nearly all research on FLASH to date has been with 
relatively large single fractions. As such, demonstrating the FLASH effect in fractionated 
schedules has important clinical relevance. Similarly, as much of clinical radiation 
therapy across disease sites is given as part of combined modality cancer treatment, an 
important question is whether the FLASH effect holds up in the context of systemic 
therapies. Such experiments are only starting to be done. 
 
A major practical limitation to clinical translation of FLASH is technological. To date, 
preclinical FLASH irradiation of small animals and small, superficial targets in larger 
animals has been possible using modifications of existing irradiation systems that are 
capable of producing FLASH dose rates when limited to small volumes (of up to a few 
cubic centimeters), including electron linear accelerators (56,68), a synchrotron light 
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source producing kilovoltage energy x-rays (69), and certain proton accelerators 
(67,70). However, recent advances in linear accelerator science and radiofrequency 
power generation and distribution technologies have led to prototypes of compact, high-
efficiency linear accelerators suitable for producing high-energy x-rays (in the 
megavoltage energy range) or very high-energy electrons (exceeding 100 MeV energy) 
capable of treating large-volume, deep-seated targets at FLASH dose rates. In 
particular, Stanford University and SLAC National Accelerator Laboratory are engaged 
in a program to develop a medical linear accelerator system based on these 
technologies, called pluridirectional high-energy agile scanning electronic radiotherapy 
(PHASER), designed to deliver highly conformal FLASH intensity-modulated radiation 
therapy to general radiation therapy targets (71). The technical motivation for 
developing this technology was as a fundamental solution to the problem of uncertainty 
owing to organ motion, by combining rapid volumetric image-guidance and treatment 
delivery that could be completed faster than the time scale of physiologic motion. The 
same delivery speed would enable clinical evaluation of FLASH biological effects. 
 
Can clinical testing of FLASH begin without a complete understanding of its biological 
mechanisms of action? A better understanding of mechanisms from preclinical studies 
would likely inform more optimal designs of clinical trials. Arguably however, it is 
possible to design some rational clinical trials without extensive understanding of 
mechanisms – indeed, our mechanistic understanding of even our current standard of 
care treatments is far from complete. Moreover, with thoughtful design of translational 
endpoints, clinical trials will facilitate our mechanistic understanding of new treatment 
modalities such as FLASH and ultimately may be essential for it. 
 
Considering trials that could be done with slight modifications of existing technology, 
one example strategy would be to start with phase 1 trials of FLASH electron beam 
therapy for superficial tumors such as skin cancers, including selected squamous cell, 
basal cell, or melanoma cancers. Ideal tumors to evaluate would be those of small to 
moderate size and location amenable to surgical salvage (in the case of incomplete 
tumor control) and/or reconstructive surgery or skin grafting (in case of late skin injury or 
radionecrosis). In this setting a reasonable strategy would be to test single fraction or 
hypofractionated FLASH regimens starting at doses high enough to produce relatively 
high tumor control probability and moderate risk of skin injury based on conventional 
dose rate data, such as 20-25 Gy single fraction. This clinical scenario lends itself 
readily to collection of translational endpoints such as serial biopsies for histologic, 
genetic, and immunologic analyses. Alternatively, FLASH radiotherapy could be 
administered preoperatively to skin tumors planned to undergo definitive surgical 
resection to assess biomarkers of tumor response, normal tissue injury, and 
inflammatory/immunologic responses. In fact, a phase 1 trial of electron beam FLASH 
for skin lesions has already been initiated at Lausanne University, and results of their 
first patient treated for T-cell cutaneous lymphoma have recently been published (72). 
 
The near future implementation of technology such as PHASER or proton therapy 
cyclotron-based FLASH that would allow delivery of radiation to a full range of target 
volumes with current state-of-the-art conformity but at FLASH dose rates would afford 
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unique opportunities for randomized clinical trials. Historically, trials comparing different 
radiation delivery modalities, for example IMRT vs. 3-D conformal RT or proton vs. 
photon, have been hampered by confounding variables because the fundamentally 
different dose distributions being compared could produce outcomes that were 
unanticipated prior to insights gained from more mature clinical experience. For 
example, in the early days of IMRT for head and neck cancers, an exclusive emphasis 
on parotid gland sparing led to plans with increased oral cavity dose and concomitant 
toxicity. In this way, engaging too early in randomized clinical trials of a new modality 
before understanding its optimal use risks prematurely concluding a lack of benefit or 
even seemingly proving a detrimental effect. However, in the case of FLASH, given a 
delivery system that can produce high quality conformal treatments, it would be possible 
to compare FLASH vs. conventional dose rate plans that are identical in every way – 
dose and fractionation, target delineation and margins, dose distribution (identical dose-
volume histograms for every organ), and the skill and effort of the planner – except for 
speed of delivery, isolating that as the only variable. After creating one optimized plan, 
randomization could be simply on whether FLASH is “switched on.” 
 
With such a capability, it would be possible empirically to test whether FLASH provides 
an advantage in different clinical scenarios. A reasonable approach would be to conduct 
randomized phase 2 studies using standard of care regimens, including stereotactic 
ablative (SABR) and conventionally fractionated radiotherapy (CFRT), for selected 
indications. Particularly attractive settings would be those in which: (1) there is currently 
a high incidence of measurable toxicity with the best standard of care, e.g., concurrent 
chemoradiotherapy for head and neck cancers or pediatric brain tumors in which whole 
cranial irradiation is used; (2) there is a high incidence of otherwise readily measurable 
early or delayed tissue damage, e.g., lung fibrosis on CT imaging after SABR; (3) 
accessible anatomic sites (by endoscopy or direct visualization, e.g., bulky cervix 
cancer) amenable to serial biopsies for mechanistic studies. The initial focus should be 
on scenarios for which there is the potential to observe a large effect size, especially on 
normal tissue sparing, should one exist. Equipoise is facilitated in that the control arm 
would be the best current standard of care, there is no suggestion from preclinical or 
even historical clinical data of an adverse effect of higher dose rates, and the technical 
objective of improved motion management through rapid treatment is valid independent 
of potential biological benefits. 
 
In conclusion, FLASH has the potential to be a paradigm shift in curative radiation 
therapy with preclinical evidence of fundamentally improved therapeutic index. While 
much remains to be understood about the mechanisms underlying the phenomenon, a 
rational approach to initial clinical testing is possible, and will contribute to a mechanistic 
understanding. Elucidation of the mechanisms through preclinical and clinical 
translational research will inform more specific and innovative clinical trial designs in the 
future, such as optimal combinations with oxygen modulation, immunotherapy, or other 
potentially biologically synergistic approaches. 
 
Clinical trial design and comparative effectiveness. 
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Technological advances in radiation oncology treatment planning and delivery have 
generally not been tested in comparative effectiveness trials but have been marketed 
based on a so-called 510(k) pre-market clearance from the U.S. Food and Drugs 
Administration (FDA). However, the novel radiation delivery methods discussed here 
are different: SFRT and FLASH-RT involve novel biological mechanisms that will need 
to be tested in well-designed controlled clinical trials before being widely adopted in 
routine clinical care. These innovative radiation therapy methods are no different from 
the biological hypotheses tested in the large time-dose-fractionation trials successfully 
conducted over the last 25 years in many tumor sites (73),  or the combined modality 
trials of chemo-radiation therapy or radiation-immune-oncology combinations versus 
radiation therapy alone. 
Once the clinical target volume is defined, a traditional course of radiation therapy can 
be described using only a handful parameters such as radiation modality, total dose, 
dose per fraction, overall treatment time, and some indication of dose uniformity in the 
target volume. In contrast, SFRT involves many more degrees of freedom for example 
the peak-to-valley dose contrast, the spatial frequency of peaks and valleys, the three 
dimensional ‘lattice’ of dose peaks delivered. The relative biological importance of these 
metrics and how these will interact with dose-fractionation in the temporal domain as 
well as with other anti-cancer modalities remain to be defined. One obvious issue that 
needs clarification is whether a spatial shift of the dose-lattice from one fraction to the 
next would essentially negate the effect. Similarly, FLASH-RT has typically been 
delivered as a single fraction in the pre-clinical setting. This would essentially make the 
4R’s of radiotherapy (repair, reoxygenation, regeneration, and redistribution) irrelevant. 
However, from a clinical perspective, the relevant comparator would arguably be a 
fractionated, possibly hypofractionated, schedule delivered at standard acute dose-rate. 
Whether the “FLASH” effect gradually disappears with decreasing ultra-high dose rate is 
not clear. With all these delivery methods, carefully planned and conducted preclinical in 
vivo experiments will undoubtedly be required to develop a rational roadmap for 
preclinical to clinical translation. 
Several of the challenges in dosimetry, quality assurance, radiobiology, and clinical 
case selection have been discussed above. From a statistical design perspective, the 
most obvious consideration is that the relevant patient-level benefit must be quantified 
in terms of a therapeutic ratio, i.e. a risk-benefit estimation. While some of these 
methods have been introduced in a compassionate way in the treatment of single 
cases, the systematic first-in-man trials should be designed as phase I/II dose 
escalation studies. The aim of these studies would be to establish a recommended 
schedule for a subsequent comparative-effectiveness trial with standard radiation 
therapy as the comparator. Because of the large patient-to-patient variability in 
outcomes, the early phase trials should preferably be randomized. Adaptive trial 
designs with relatively rapid dose titration may be attractive. While the aim of the early 
trials would be to establish a radiation dose that achieves isoeffectiveness with respect 
to adverse events compared with standard radiation therapy, a – possibly relaxed – 
stopping rule related to efficacy should be enforced for patient safety. This trial will need 
to have a sufficient sample size to arrive at a reasonably accurate estimate of the 
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Recommended Phase 3 Dose (RP3D), c.f. the RP2D concept used in phase I drug 
trials. 
Phase III trials with dual primary endpoints will be required to show a meaningful benefit 
in terms of therapeutic ratio: demonstrating superiority with respect to toxicity and at the 
same time non-inferiority within a given margin in terms of tumor control; or, 
alternatively, superiority with respect to tumor control and non-inferiority with respect to 
late adverse effects. A trial powered to show sparing of adverse effects is not going to 
be conclusive unless it also has the statistical power to show that this normal tissue 
sparing can be achieved without an unacceptable loss of efficacy.  
Clinically relevant non-inferiority and superiority margins are required to make the trial 
outcome practice-changing. This will require large sample sizes that are only achievable 
in large co-operative group trials, possibly inter-group trials across many of the 
established clinical research networks. 
 
Overall summary and conclusions 
Progress in science depends on change and innovation, and the field of radiotherapy is 
no exception, as it has potential advancements in physics, chemistry and biology all 
aimed at improving the therapeutic index.  This report has highlighted some alternative 
dose delivery modalities able to exploit certain differences between normal tissue and 
tumors that have resulted in some rather unexpected beneficial effects now 
substantiated in multiple labs (FLASH) and empiric observations for other SFRT 
techniques.  While the detailed description of how volume sparing in the “valley” region 
of MRT promotes tumor kill and normal tissue recovery awaits further investigation, 
present results point to a fascinating paradigm with potential considerable clinical 
promise. Similarly, FLASH-RT explores a different range of dose rates compared with 
the ‘traditional’ dose-rate effect, where decreasing dose rate is associated with an 
improved therapeutic ratio. For this and other reasons, FLASH-RT has caught the field 
by surprise, where a relatively straightforward change in beam delivery has led to 
significant improvements in the therapeutic index, heretofore unrealized by other 
advancements in medical physics.  One fascinating observation is that pencil beam 
proton GRID techniques might blend the advantages of both SFRT and FLASH (since 
the dose-rates at the distal edge of the beamlets might be in the FLASH dose-rate 
range) (74).  Table 1 is a primer and quick reference/summary of this meeting report 
and the discussion to date by members of the program and assembled working groups 
regarding the state of research and translation potential for each sub-area of the 
broader movement to find innovative uses for ionizing radiation. 
 
The capability of FLASH-RT to ameliorate normal tissue complications in the brain as 
well as several other organ sites while exhibiting isoefficient (or potentially even 
improved) tumor control has stimulated significant excitement in the field, and is poised 
to change the landscape of current practice in radiotherapy.  While beam and pulse 
characteristics along with protocols for delivering single versus fractionated FLASH-RT 
remain to be fully optimized, these advancements have defined new avenues for the 
field and should be pursued with judicious and rigorous research (75).  While the need 
for accurate dosimetry and precise dose delivery have always been at the forefront of 
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clinical safety and practice, other concerns revolving around these new modalities 
should not stifle their development.  As a recurrent theme that remains relevant, change 
is continually needed for the optimal advancement of new technologies that aim at 
improving health care. 
 
Presented at the workshop and published separately from this report (due to the need 
for information from NCI workshops to be available within a year) is an editorial 
regarding implementation of new technologies in routine clinical practice (68).  As noted, 
this workshop has led to the establishment of physics, biology and clinical working 
groups that can take the enthusiasm, observations and data forward into the necessary 
studies for appropriate clinical implication for radiation oncology alone and in 
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Figure 1. Proposed biological mechanisms of SFRT 
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